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Abstract
The Second International Workshop on CMV & Immunosenescence was held in Cambridge, UK, 2-4th December,
2010. The presentations covered four separate sessions: cytomegalovirus and T cell phenotypes; T cell memory
frequency, inflation and immunosenescence; cytomegalovirus in aging, mortality and disease states; and the
immunobiology of cytomegalovirus-specific T cells and effects of the virus on vaccination. This commentary
summarizes the major findings of these presentations and references subsequently published work from the
presenter laboratory where appropriate and draws together major themes that were subsequently discussed along
with new areas of interest that were highlighted by this discussion.
Background
The first International Workshop on CMV & Immuno-
senescence was held in Tubingen, Germany, December
2009. The discussions focused on trying to define what
immunosenescence is exactly, the phenotypes of the
cells associated with it and what evidence was available
that long term carriage of HCMV into old age was det-
rimental to health as assessed either by measuring all-
cause mortality or degradation of the immune system
such that older HCMV-seropositive individuals respond
less well to neo-antigens such as seasonal influenza vac-
cination. The outcome of the first workshop was sum-
marized in this Journal by Pawelec et al. [1]. The
attendees at that workshop decided that it would be
extremely valuable to meet again in a year’s time with a
remit to update participants on progress on questions
left open from the first meeting’s discussion, and to
extend participation to other scientists omitted from or
unable to attend the first workshop. The Second Inter-
national Workshop on CMV & Immunosenescence was
duly held in Cambridge, UK, 2-4th December, 2010. The
second meeting format was modified to include a day of
formal seminar presentations with some emphasis on
the presentation of data that addressed open questions
highlighted in the first meeting. This was then followed
by a half-day round-table discussion.
The seminar presentations covered four separate ses-
sions: cytomegalovirus and T cell phenotypes; T cell
memory frequency, inflation and immunosenescence;
cytomegalovirus in aging, mortality and disease states;
and the immunobiology of cytomegalovirus-specific T
cells and effects of the virus on vaccination. This com-
mentary summarizes the major findings of these presen-
tations and references subsequently published work
from the presenter laboratory where appropriate and
draws together major themes that were subsequently
discussed along with new areas of interest that were
highlighted by this discussion.
Cytomegalovirus and T cell phenotypes
The impression left on the immune system of the
majority of the population (as characterized by changes
in T cell phenotype) following primary CMV infection
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and its subsequent life-long carriage is well-established
and uncontroversial. Nonetheless, certain special popu-
lations may resist the effects of CMV infection on their
immune signatures [2]. As these data stem from obser-
vations in exceptionally long-lived families, and because
such longevity is likely influenced by multiple genes,
sharing of more or less of the latter in the general popu-
lation is likely to make the impact of CMV a continuous
rather than a discrete variable. This complicates inter-
pretation of data treating the presence of CMV infection
as simply present or absent (ie. seropositive or seronega-
tive). Speiser (Lausanne) presented evidence that the
late-differentiated HCMV-specific CD8+ T cell clones in
the periphery had a restricted T cell receptor usage and
particular clonotypes segregated with particular states of
differentiation. Interestingly, once established, these pat-
terns were stable over many years. This may again sug-
gest a subtle genetic control of anti-CMV surveillance.
Vescovini and Sansoni (Parma) made available their
unpublished data on an immune phenotype and fre-
quency study in a cohort of 125 HCMV-seropositive
elderly subjects aged between 60-100 years. The study
concluded that there was a significant correlation
between the magnitude of CMV-specific CD4+ T-cell
responses and accumulation of effector T-cells within
the CD4+ T cell compartment. There was also a signifi-
cant correlation in the magnitude of CMV-specific CD8
+ T-cell responses and number of total CD8+ T-cells as
well as the number of both memory and effector CD8+
T-cells. The study did not find significant correlations
between the magnitude of CMV-specific T-cell
responses and a shortage of either CD4+ or CD8+ naïve
T-cells. In this instance, the presence or absence of
CMV infection did seem to behave as a discrete variable
in its effects on naïve T cells. These findings emphasize
the over-riding impact of CMV infection per se on com-
monly-measured immune parameters, and those com-
monly attributed to immunosenescence (ie. loss of naïve
T cells). Solana (Cordóba) presented further evidence
that there is an accumulation of CD8+ CD28- T cells
with short telomeres that tend to also acquire inhibitory
NK receptors in healthy elderly people. He noted that
similar changes can be seen in chronic stimulation situa-
tions such as patients with melanoma, HIV infection
and RA. The HCMV pp65-specific T cells from elderly
individuals were found to be heavily enriched in
CD45RA+ CD27- CD28- CCR7- cells and evidence was
presented that these had a low proliferative capacity fol-
lowing specific stimulation with pp65 peptides [3]. He
noted that similar phenotype changes can be seen in
HCMV-pp65 specific CD8 T cells in solid organ trans-
plantation that were associated with age and with epi-
sodes of CMV replication after transplantation. In
addition a correlation was observed between the
duration of HCMV replication after transplantation and
the percentage of EMRA HCMV-specific CD8+ T cells
[3,4]. All these data are consistent with the potential of
some (CMV, HIV) but not all (eg. HSV, HCV) [5]
chronic viral infections to drive the acquisition of
immune signatures associated with “immunosenes-
cence”. However, the relationship, if any, between such
immune signatures and mortality in any populations
except the very old (> 85 yr) Swedes investigated in the
OCTO/NONA studies [6] still remain to be established,
as does the question of whether the contribution of
CMV infection is causative or merely reactive.
Kern (Brighton) presented a study to establish the
most relevant target proteins recognized by ageing
CMV-positive individuals so that a knowledge base can
be established to inform researchers which proteins to
use for monitoring and analyzing T-cell responses. Cur-
rently the focus is very much on pp65 and IE-1; how-
ever, many other proteins are recognized by T cells and
there is good reason to believe that studies on pp65 and
IE-1 alone are not representative of the entire immune
response to CMV. The reported study investigates T-
cell responses to 19 ORFs (previously identified by Syl-
wester et al. [7] to be the most important target pro-
teins) in approx. 100 older people (including 50 people
over 75+). The study addresses a spectrum of different
T-cell functions with respect to each target protein and
it will facilitate a wider, more comprehensive view of
the T-cell response to CMV in older age. The study will
be concluded in 2011 and results are expected to be
published in 2012.
T cell memory frequency, inflation and
immunosenescence
Setting aside the difficulties in proving that accumula-
tion of cytomegalovirus-specific T cells with the distinct
phenotypic and functional characteristics described
above are responsible for an increase in all-cause mor-
tality or a decreased ability to mount good quality
responses to new antigens, and whether their specificity
is important in this context, both Hill (Portland) and
Klenerman (Oxford) addressed the biological phenom-
enon of “memory T cell inflation” using the murine
CMV model. Klenerman has investigated the mechan-
ism that leads to memory inflation while Hill has asked
what happens to the CMV-specific T cell response if
cytomegalovirus replication is inhibited. This latter
investigation is of particular importance as it has been
suggested that elderly HCMV-seropositive people may
benefit from anti-herpes virus chemotherapy. The ratio-
nale would be that anti-viral therapy would decrease
HCMV replication and thus chronic antigenic stimula-
tion which might reduce the frequency of the late-stage
differentiated T cell pool and thus allow an increase in
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the naïve pool with the hope that T cell responses to
neo-antigens would improve. Klenerman addressed the
issue of why memory inflation is triggered by some anti-
gens but not others. Memory inflation is defined as the
inordinate increase in frequency of CD8+ T cells speci-
fic for certain antigens with time post-exposure to anti-
genic stimulation. The phenomenon has been seen with
CMV, HIV and parvovirus B19 infections; however, cer-
tain antigens from these viruses but not to others within
the same virus are found to cause this effect, and other
viruses do not cause it at all. The “inflating” cells have a
distinct transcriptional profile as compared to non-
inflating T cells from the same animal. It is not clear if
persistence of viral antigen is required regardless of viral
reactivation or why some epitopes cause inflation while
others do not. The Klenerman study concluded that
viral replication was not required for memory inflation
and that epitopes that showed inflation had a reduced
dependence on the immunoproteasome [8]. Hill also
addressed memory inflation in MCMV specifically to
understand what happens to the T cell response if cyto-
megalovirus replication was inhibited? Using two sepa-
rate models of replication and spread-deficient virus
that still establishes viral latency, memory T cell infla-
tion nonetheless occurred and was maintained. Inhibi-
tion of viral replication by inhibiting viral DNA
replication also had no effect on the T cell response
over time [9].
Taking these two studies together, the data from the
murine model would suggest that treating humans with
anti-herpesvirus chemotherapy may not reverse the
effects of HCMV on the memory T cell compartment.
Most studies of this type have been carried out in
humans or mice, but Nikolich-Zugich (Tucson) pre-
sented data looking at the maintenance of T cell mem-
ory in the face of CMV and ageing using the Rhesus
CMV (RhCMV) model. The study examined the
RhCMV CD4+ and CD8+ T cell responses in adult ani-
mals aged 7-10 years and aged animals 19-26 years old.
The study concluded that there was no difference in the
phenotype, numbers, proliferative capacity or functional-
ity of the T cells between the two groups of animals and
that there was no evidence for either a functional
decline or exhaustion in aged animals [10]. This was
further corroborated by their study using systemic HSV-
1 infection, which closely models MCMV infection in
mice [11]. However, given that CMV and HSV have
very different effects in humans [5], this result in mon-
keys is perhaps not unexpected.
Further, in the context of the impact of HCMV on
immune signatures, Sauce (Paris) presented her studies
on the impact of HCMV infection in young adults thy-
mectomized during early childhood. The data presented
suggested that HCMV infection tended to cause the
exhaustion of the naïve T cell pool [12]. Moreover, in a
separate study in HAART-treated HIV patients, mount-
ing strong CMV-specific responses appeared to impact
on both naïve CD4+ T-cell counts and their recovery
upon antiretroviral therapy [13]. In these two clinical
settings, T cell responses to HCMV have a profound
impact of the immune system as a whole. In the special
cases of thymectomy and HIV infection, the impact of
CMV may therefore be more pronounced and easier to
determine unequivocally.
Further discussion considering the impact of CMV on
immunosenescence led to revisiting the question of
what is the definition of T cell senescence? Senescence is
a term generally used to describe replication incompe-
tence of fibroblast cells after a certain finite number of
population doublings. Replicative senescent cells have
been defined in the brain and in cardiology but how
should it be done for the immune system? Are there
any such cells in the constantly-renewing T cell com-
partment? The use of the term in describing CMV-spe-
cific T cell populations is more controversial as it is
acknowledged that many of the late-differentiated T
cells do retain replication competence. However, it
should be noted that their definition by CD45RA
expression and lack of either CD27 or CD28 or both
does not define a homogeneous cell population, as
many more markers can be added (eg CD57, KLRG1,
PD1) to further sub-divide late-stage T cell populations
which may yet include an antigen-specific population
that is indeed unable to divide further. Another compli-
cation is that the term “senescent” is also being used to
imply non-functionality, whereas data from many
laboratories in human, rhesus and murine systems have
shown that late-differentiated cells maintain function. In
vivo, the work of Macallan (London) suggests that these
cells turn over only very slowly. There was a feeling that
we might have become too fixated on the replication
capacity of these cells. Of more importance could be
their direct effector function. Indeed, the suggestion was
made (Pawelec, Tübingen) that some of the defining
characteristics of senescent cells which T cells share
with the “classic” fibroblast model (ie. lack of prolifera-
tive capacity, apoptosis resistance, inflammatory media-
tor secretion) are not markers of senescence in the
sense that they are detrimental (which by definition of
the term “senescence” has to be shown to justify its
use). Instead, one could view these properties as cellular
protection mechanisms responsible for maintaining an
active population of cells required for immunosurveil-
lance, ie. required for prevention of peripheral clonal
deletion of necessary cells. In fact, there is some evi-
dence from the longitudinal NONA studies that at the
terminal phase of life in the very elderly, the number of
CD8+ clonal T cell expansions, most of which are
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specific for CMV, is inversely related to remaining survi-
val time [14]. More recently, data from a 7-year follow-
up of subjects 88 years old at baseline in the Leiden 85+
study has shown that the degree of accumulation of
late-differentiated CD8 cells, putatively mostly specific
for CMV, is positively associated with longer survival
(Derhovanessian et al., 2011 submitted).
Discussion of CMV and Immunosenescence - Is it
associated at all?
If chronic challenge with CMV contributes to causing
immunosenescence, it might be expected that more fre-
quent CMV reactivation would accelerate this process.
However, it is not known whether CMV does reactivate
more frequently in the elderly. It was felt that higher
HCMV IgG levels might reflect this, but in many sick
people they stay the same, so did this mean that HCMV
was not reactivating? A study of elderly people suffering
from acute bacterial infections (e.g. S. pneumonia, E.
coli, S. aureus, K. pneumonia) did not show any reacti-
vation of CMV infections measured by IgM antibodies
(n = 20). However, serology does not measure viral
levels so this is a mute point. Nonetheless, it was
strongly felt by a number of clinicians involved with the
care of older adults that “It is very unlikely that CMV
reactivation and viral replication is a problem in the
very elderly.” Wang (Baltimore) provided some evidence
for this, indicating that a small-scale study of older
adults (n = 40) categorised as either frail or not frail
showed no HCMV DNA in serum in either group, with
the exception of one frail individual who had 8 copies/
mL (this would be on the very edge of detection). Peo-
ple were reminded that VZV reactivation occurs in the
elderly and that it had been correlated with decrease in
CD4 cells and decrease in IFN gamma responses [15].
Data on CMV are lacking.
HCMV in aging, mortality and disease states
In the studies of Swedish octogenarians and nonagenar-
ians (OCTO and NONA) an immune risk profile (IRP)
associated with increased mortality on 2, 4 and 6-year
follow-up was defined, comprising reduced B cell num-
bers, an inverted CD4:CD8 T cell ratio, increased fre-
quency of CD8+ CD28- T cell populations, a poor
proliferative response to mitogen stimulation and
HCMV seropositivity. Strindhall (Jönköping) outlined
the results from a new study examining whether this
immune profile is already established in a cohort of
much younger older people in their sixties, the HEXA
study. The initial results show that this profile does
exist in hexagenarians. Almost 15% of the cohort had an
inverted CD4:CD8 ratio, a frequency very similar to that
seen in 85-year-olds, and these individuals also showed
characteristics previously identified in IRP individuals of
the very old. The study now has the opportunity to
examine morbidity and mortality to determine if this
truly defines a risk profile in people only in their sixties.
It is clearly of great importance to establish if long-
term carriage of HCMV is associated with an increased
likelihood of all-cause mortality. A number of studies
addressing this issue have already been published
[16,17] and the results from further studies were pre-
sented at this meeting. Wang spoke about a study of
635 70-79 year-old women living in the community.
The results demonstrated that women in the highest
HCMV IgG quartile had a significantly higher incidence
of frailty as compared to HCMV-seronegative women at
baseline. Furthermore, CMV IgG concentration in the
highest quartile also increased the risk of five-year mor-
tality, independent of potential confounders including
cardiovascular disease [18]. Work on data taken from
the National Health and Nutrition Examination study
(NHANES) III concluded that CMV-seropositivity was
associated with an increased risk of all-cause mortality
in > 14,000 adults at least 25 years of age followed for >
10 years; especially individuals with a raised inflamma-
tory marker (C-reactive protein CRP) were at a higher
risk of both all-cause mortality and cardiovascular-asso-
ciated mortality [19].
It should be noted that not all studies do show such
an association, and that when they do, this does not
necessarily imply causality. Maier (Leiden) presented
results from four cohorts comprising the Leiden 85-plus
study, Danish Twin study, Leiden Longevity Study and
the PROSPER study with a mortality follow-up of 6 to
12 years. The results did not support a relationship with
CMV serostatus or antibody levels in all-cause mortality
or inflammation markers in any of the 4 cohorts. Con-
sistent with this, a recent study presented at the 2011
Cytomegalovirus Workshop in Nuremberg, Germany by
Stuart Adler concerned a prospective longitudinal study
with an 18 year follow-up of 915 patients undergoing
coronary angiography. It was concluded that neither
CMV seropositivity nor antibody levels were associated
with longevity irrespective of the presence or absence of
coronary heart disease (personal communication). These
data are therefore different from a smaller, shorter,
study from Finland on one-third the number of patients
with stable cardiovascular disease which did show a
positive relationship between highest quartile IgG anti-
body titer and mortality [16]. This crucial question
therefore remains to be resolved, as discussed intensely
at the Workshop.
Discussion on Cohort studies of all-cause mortality CMV
seropositive vs negative
It was felt that defining the confounding factors and
how to correct for them is crucial in these analyses,
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although it is not clear what best practice is. The dis-
similar populations in these cohort studies likely also
contribute to the divergent findings on the association
between HCMV carriage and mortality. However, the
requirement for standardization in the quantitation of
HCMV IgG levels would also be an important step and
was discussed further along with other metrics that
require standardization. These are outlined in the new
questions section of this report.
Discussions on the Immune risk profile, IRP
The IRP was defined in the Swedish OCTO and NONO
studies, but it was left as an open question if the IRP
actually applies generally to human populations? It was
suggested that a cohort in Spain does show the IRP
(Solana) and Moss has cohorts in the UK which also
show the IRP; however, not all cohorts do, as an aged
community in the mountain region in Sicily do not
show the IRP (Caruso, Palermo). However it was felt
that this population was not old enough as so far we
only know that the IRP is relevant from age 85.
The IRP does not take into account the absolute num-
ber of naïve T cells, nor the absolute numbers of mem-
ory cells: the IRP was based on percentages. The
percentage of CD8+CD28- cells was part of the IRP, but
it is also clear that there is an increase in the absolute
number of these cells per ml of blood in the risk group.
This raises the question at what levels of naïve CD4 or
CD8 T cells do people start to experience problems?
Sauce suggested from her work that a level of < 50
naive CD8+ T cells per μl and < 100 naïve CD4+ T
cells is crucial, although different specific cut-offs might
be relevant at different age ranges. A further refinement
of the accumulation of CD8+ CD28- T cells defined in
the IRP was suggested to take into account lymphope-
nia, as it was felt that those individuals who were both
lymphopenic and had large CD8+ CD28- expansions
had a poor outcome.
The immunobiology of cytomegalovirus-specific T
cells and effects on vaccination
Macallan presented a study to determine why highly
differentiated HCMV-specific CD8+ T cells accumulate
and in particular to distinguish accumulation due to
rapid proliferation versus long-term persistence due to
impaired apoptosis. They demonstrated that these
expansions are often oligoclonal and these clones are
stable over many years. In addition, comparison of CD8
cells from young and old donors showed no difference
in either proliferative activity or cytotoxic function.
Assessment of in vivo turnover rate by deuterated glu-
cose experiments suggest that the cells have a low pro-
liferative rate in vivo and as such probably accumulate
with time rather than by proliferation [20].
Henson (London) reported that late-stage memory
cells also express inhibitory receptors such as PD-1 and
KLRG1 and this tends to be higher on T cells from indi-
viduals who are HCMV-seropositive. This has been
observed by many others, including several Workshop
participants and seems to be a general finding. She
showed that blockade of PD-1 increased proliferation of
these cells and no additive effect was seen with dual
PD-1 and KLRG-1 blockade, nor did it increase telomer-
ase activity.
The idea that CD8+ memory T cells compete for
space in a T cell compartment that is constrained in its
maximum size has led to the suggestion that over-abun-
dant memory T cells such as those seen in people with
latent HCMV carriage could have a detrimental effect
by displacing naïve or other memory T cells. Could the
occupation of the “immunological space” by large and
inflating HCMV-specific T cells contribute to immuno-
senesence? Van Lier (Amsterdam) presented data from
a study comparing the frequency of EBV- and HCMV-
specific T cells in the blood and lymph node (LN) of
donors showing that while the percentages of EBV-spe-
cific T cells were comparable between blood and LN,
HCMV had a much lower LN frequency which included
the late-differentiated cells as determined by CD45RA+
and CD27- phenotyping. The study concluded that
strong immune responses to HCMV were unlikely to
restrict space for naïve or other memory T cells in LN.
Although these results are intriguing, the impact of
aging was not addressed in that study. In particular, as
CMV infection has been shown to impair the response
to a co-resident EBV infection in middle-aged and
elderly persons, but not in young adults [21], the study
raises a very important question. If CMV infection does
not impair the survival of naive T cells in the LN, the
major reservoir of naive T cells, how is the decline of
naive T cells in the peripheral blood of CMV-seroposi-
tive versus CMV-seronegative persons explained?
[22,23]. The ability of CMV to significantly decrease
peripheral naive T cells in young persons with poten-
tially intact or at least more residual thymic T cell gen-
eration indicates that CMV infection may not only drive
peripheral naive T cell exhaustion but also affect T cell
generation in the thymus. Accordingly, there is a need
to delineate the mechanism of naive T cell generation/
exhaustion and CMV infection as well as to analyze the
impact of CMV infection not only in the peripheral
blood, but also in lymphoid and extra-lymphoid organs,
to improve our understanding of HCMV-specific T cell
migration, differentiation and expansion throughout life.
Westendorp (Leiden) presented a study on the effi-
cacy of influenza vaccination in a cohort of elderly indi-
viduals living in care facilities. The study design
encompassed a number of different dosing regimes and
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was able to examine influenza seroconversion in relation
to HCMV seropositivity. The study concluded that in
this particular cohort previous CMV infection does not
explain poor responsiveness to influenza vaccination
and as such does not support CMV infection as being
the origin of this dysfunction in the immune system of
these older people [24]. These results contrast with an
earlier study [25], in which elderly HCMV-seropositive
individuals where shown to respond less well to influ-
enza vaccination. It should be noted that only the domi-
nant H3N2 strain of influenza strain was used in the
den Elzen study as opposed to all three seasonal strains
in the Trzonkowski study, and that the weakest correla-
tion was between HCMV seropositivity and seroconver-
sion to H3N2 in the latter. It is clear that this important
area deserves further study. If HCMV does drive immu-
nosenescence, a tangible outcome such as poor vaccina-
tion responses would be predicted and importantly this
evidence could support a rationale for a modified vacci-
nation protocol in elderly HCMV seropositive
individuals.
New Questions raised by the discussions
Standardization - HCMV serotesting the means of
detection, the measurement of viremia and T cell assays?
It is not at all clear what antibody responses are actually
being measured when HCMV serotesting is reported.
There is a requirement for standardization in the CMV
antigens that are used on the plate coatings. This is of
particular importance as studies of the effect of HCMV
on mortality or measures of health often group patients
based on the level of antibody response (into four quar-
tile groups). Comparison of different studies is not
helped if what is being measured in one study/labora-
tory is not the same as another study/laboratory. It was
felt that there is a need for standardization such that
results can be compared, and for further sophistication
in dissecting out antibody repertoires. The subclass of
IgG is never considered; IgM titer rarely, the avidity of
antibody never. All these factors could be informative.
In a similar fashion, concerns about the comparability
of T cell assays between groups in the field was felt to
be an issue. Very little standardization was evident
between different flow cytometry-based T cell assays.
Parameters that were of particular concern were: the
use of fresh vs frozen PBMC samples, the anti-coagu-
lants used to collect blood samples, the combination of
cell surface phenotypes used to determine T cell subpo-
pulations (variations on the use of CD27 or CD28 with
CD45RA eg). These concerns are not unique to this
field. Kern noted that there was a move to adopt a stan-
dardization provision of minimal information on T cell
assays (MIATA). Similar concerns were raised from a
series of conferences on the measurement of antigen-
specific immune responses (MASIR). A goal for presen-
tation at the next meeting is to determine a set of
recommendations for standardization along the lines
outlined in [26,27].
Where are the CMV-specific T cells, where is the
reservoir, is it the spleen? Or perhaps marginal pools?
This reservoir, and there may be more than one, seems
dynamic and provides rapid access to the blood, as per-
ipheral blood cell numbers show rapid fluctuations. The
stress hormone adrenaline can regulate this exchange
with the blood. Bosch (Birmingham) presented data
showing that physiological stressors (exercise, psycholo-
gical stress) cause swift (< 10 minutes) and robust (up
to +300%) release of differentiated (CD27-CD28-CCR7-)
memory CD8+ T cells as well as CMV-specific CD8+ T
cells into peripheral blood. Using pharmacological infu-
sion and blockade studies, he provided evidence that
this release is regulated by the stress hormone adrena-
line and dependent on activation of b-adrenergic recep-
tors. This finding coincides with reports of upregulated
expression of b2-adrenergic receptors on differentiated
T cells [28]. Significantly, 1 to 2 hours post-stress these
cells cleared from the blood, with cell numbers dropping
to 70% below resting levels [29,30]. Bosch suggested that
this may reflect a rapid egress into tissue.
In accordance with their effector-memory phenotype,
CMV-specific T cells should preferentially migrate to
and reside in extra-lymphoid organs and the bone mar-
row. Yet the frequency of CMV-specific CD8+ and CD4
+ T cells in the human bone marrow is similar [31,32]
or even lower compared to the peripheral blood [33].
Nonetheless, Letch et al. did show that CMV-specific
CD8 cells with a central memory phenotype, while pre-
sent in low frequencies in the peripheral blood, were
present at higher levels in the BM. Moreover, CMV-spe-
cific T cells from the BM underwent greater clonal
expansion in vitro than PB cells. This might also be of
practical importance in transplantation (independently
of any ageing considerations). Although the impact of
aging on the frequency of CMV-specific T cells in the
bone marrow has not yet been addressed, the currently
available data may support a role of the bone marrow as
a reservoir for highly functional CMV-specific central-
memory T cells (Herndler-Brandstetter, Birmingham).
Are large expansions of HCMV specific T cells
detrimental?
Moss asked us to directly address the issue that if CMV
has any association with immunosenescence, old people
without CMV must have better immune responses to
neo-antigens. It was further suggested that CMV-sero-
positive vs negative showed no correlation with inflam-
matory markers - and it would be expected that it
should. However, could there be a subset or group of
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certain individuals that are affected and this is not seen
at a population level? Moss suggested this was the case
in a cohort of CML patients where those with large
CD4+ CD28- T cell expansions with a loss of naïve cells
showed an increase in infections.
Is it how someone deals with CMV over a long period of
time which is actually important?
The Leiden Longevity Study examines familial longevity
in an F2 generation with a 30% decreased standardised
mortality rate between the ages of 40 and 80. This is
proposed to be due to a genetic influence - an enrich-
ment of “longevity-assurance” genes. The F2 subjects
studied here showed some indications of resistance to
becoming infected with CMV even when their partner
(sometimes over decades) was CMV-seropositive. More-
over, when they were infected, they did not show the
characteristically lower frequencies of naïve CD8+ T
cells and higher frequencies of late-differentiated CD8+
CD28- T cells seen in the general population [2]. They
also showed lower levels of markers of inflammation in
the plasma and less potentially inflammatory-mediated
disease (eg. type 2 diabetes). The link between CMV,
inflammation, disease, longevity and genetics is being
studied in these remarkable people.
Would treatment of CMV with antivirals have a beneficial
effect on the immune system?
Evidence from Hill’s studies suggest not! However, is
the MCMV model sufficiently close to HCMV that we
can extrapolate? In the face of the not yet sufficiently
documented (and to some extent controversial) health
risks of persistent CMV infection, it is highly speculative
whether long-term treatment with antiviral drugs will
result in any measurable health benefits. In particular,
long-term treatment with antiviral drugs may not be a
good option, as the treatment is likely to have side
effects and to facilitate viral resistance. Some people felt
that this argued in favour of the ongoing efforts to
develop an efficient CMV vaccine able to protect from
primary infection. Such a vaccine would most likely be
cost-effective in preventing from any detrimental CMV-
related impairments of the immune system.
It was felt that currently-available antivirals also have too
much toxicity and adverse-effect burden to tip the benefit-
risk balance toward warranting administration to other-
wise healthy humans. The administration of these antivir-
als to immunosuppressed transplant recipients is
warranted because of the significant morbidity and mortal-
ity caused by CMV in this patient population. If further
evidence suggests that halting HCMV replication and
reactivation confers a beneficial effect on the immune sys-
tem, the development of next-generation antivirals with
significantly less toxicity would be a high priority.
Conclusions
This 2nd Workshop was attended by twice the number
of people than the first original discussion group. The
interaction of so many additional scientists with exper-
tise in basic cytomegalovirus immunology, virology and
epidemiology was invaluable. As a group, a large num-
ber of the most important questions are being addressed
and importantly new questions are being raised and dis-
cussed which is vital for the field to move forwards. It
was proposed that a 3rd meeting should be organised
and this had overwhelming support. We are grateful to
Rafael Solana (rsolana@uco.es) for offering to do this in
Cordoba, Spain, 8-9th March, 2012.
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